Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Bringeland GH, Bader L, Blaser N, Budzinski L, Schulz AR, Mei HE, Myhr KM, Vedeler CA, Gavasso S.

Cytometry A. 2019 Mar;95(3):314-322. doi: 10.1002/cyto.a.23723. Epub 2019 Jan 27.

PMID:
30688025
2.

B cell depletion in the treatment of multiple sclerosis.

Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T.

Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23.

PMID:
30632834
3.

Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study.

Magalhaes S, Pugliatti M, Riise T, Myhr KM, Ciampi A, Bjornevik K, Wolfson C.

Int J Epidemiol. 2018 Dec 18. doi: 10.1093/ije/dyy269. [Epub ahead of print]

PMID:
30561654
4.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
5.

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

PMID:
30196837
6.

Semi-automated estimation of left ventricular ejection fraction by two-dimensional and three-dimensional echocardiography is feasible, time-efficient, and reproducible.

Myhr KA, Pedersen FHG, Kristensen CB, Visby L, Hassager C, Mogelvang R.

Echocardiography. 2018 Nov;35(11):1795-1805. doi: 10.1111/echo.14112. Epub 2018 Aug 2.

PMID:
30073701
7.

Neurofilaments and 10-year follow-up in multiple sclerosis.

Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E.

Mult Scler. 2018 Sep;24(10):1301-1307. doi: 10.1177/1352458518782005. Epub 2018 Aug 1.

PMID:
30066611
8.

α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.

Bjornevik K, Myhr KM, Beiske A, Bjerve KS, Holmøy T, Hovdal H, Midgard R, Riise T, Wergeland S, Torkildsen Ø.

Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925. [Epub ahead of print]

PMID:
29862891
9.

The economic impact of multiple sclerosis to the patients and their families in Norway.

Svendsen B, Grytten N, Bø L, Aarseth H, Smedal T, Myhr KM.

Eur J Health Econ. 2018 Dec;19(9):1243-1257. doi: 10.1007/s10198-018-0971-5. Epub 2018 Apr 21.

PMID:
29680926
10.

Severe multiple sclerosis reactivation after gonadotropin treatment.

Torkildsen Ø, Holmøy T, Myhr KM.

Mult Scler Relat Disord. 2018 May;22:38-40. doi: 10.1016/j.msard.2018.02.031. Epub 2018 Mar 6.

PMID:
29525298
11.

Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.

Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, Thorleifsson G, Gustafsson O, Johannesson A, Geirsson AJ, Thorsson AV, Sigurgeirsson B, Ludviksson BR, Olafsson E, Kristjansdottir H, Jonasson JG, Olafsson JH, Orvar KB, Benediktsson R, Bjarnason R, Kristjansdottir S, Gislason T, Valdimarsson T, Mikaelsdottir E, Sigurdsson S, Jonsson S, Rafnar T, Aarsland D, Djurovic S, Fladby T, Knudsen GP, Celius EG, Myhr KM, Grondal G, Steinsson K, Valdimarsson H, Bjornsson S, Bjornsdottir US, Bjornsson ES, Nilsson B, Andreassen OA, Alfredsson L, Hillert J, Kockum IS, Masson G, Thorsteinsdottir U, Gudbjartsson DF, Stefansson H, Hjaltason H, Harbo HF, Olsson T, Jonsdottir I, Stefansson K.

NPJ Genom Med. 2017 Aug 8;2:24. doi: 10.1038/s41525-017-0027-2. eCollection 2017.

12.

Progressive multifocal leukoencephalopathy.

Alstadhaug KB, Myhr KM, Rinaldo CH.

Tidsskr Nor Laegeforen. 2017 Dec 12;137(23-24). doi: 10.4045/tidsskr.16.1092. Print 2017 Dec 12. Review. English, Norwegian.

13.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

14.

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.

Olberg HK, Eide GE, Cox RJ, Jul-Larsen Å, Lartey SL, Vedeler CA, Myhr KM.

Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.

PMID:
29205701
15.

Break-out session highlights.

Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R.

Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042.

PMID:
29143586
16.

The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway.

Benjaminsen E, Myhr KM, Alstadhaug KB.

Seizure. 2017 Nov;52:131-135. doi: 10.1016/j.seizure.2017.09.022. Epub 2017 Oct 6.

17.

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM.

Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Review.

PMID:
28858531
18.

1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins.

Oveland E, Nystad A, Berven F, Myhr KM, Torkildsen Ø, Wergeland S.

Neurochem Int. 2018 Jan;112:267-277. doi: 10.1016/j.neuint.2017.08.008. Epub 2017 Aug 14.

PMID:
28818673
19.

Point-of-care ultrasonography in Norwegian out-of-hours primary health care.

Myhr K, Sandvik H, Morken T, Hunskaar S.

Scand J Prim Health Care. 2017 Jun;35(2):120-125. doi: 10.1080/02813432.2017.1333307. Epub 2017 Jun 8.

20.

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625. doi: 10.1136/jnnp-2016-315238. Epub 2017 Apr 1.

21.

Body size and physical exercise, and the risk of multiple sclerosis.

Cortese M, Riise T, Bjørnevik K, Myhr KM; Multiple Sclerosis Conscript Service Database Study Group.

Mult Scler. 2018 Mar;24(3):270-278. doi: 10.1177/1352458517699289. Epub 2017 Mar 13.

PMID:
28287051
22.

Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.

Wesnes K, Myhr KM, Riise T, Cortese M, Pugliatti M, Boström I, Landtblom AM, Wolfson C, Bjørnevik K.

Mult Scler. 2018 Feb;24(2):150-157. doi: 10.1177/1352458517694088. Epub 2017 Feb 1.

PMID:
28273774
23.

Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.

Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA.

Mitochondrion. 2017 May;34:32-35. doi: 10.1016/j.mito.2016.12.003. Epub 2016 Dec 23.

PMID:
28017684
24.

CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Guldbrandsen A, Farag Y, Kroksveen AC, Oveland E, Lereim RR, Opsahl JA, Myhr KM, Berven FS, Barsnes H.

Mol Cell Proteomics. 2017 Feb;16(2):300-309. doi: 10.1074/mcp.O116.064477. Epub 2016 Nov 27.

25.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

26.

The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis.

Lereim RR, Oveland E, Xiao Y, Torkildsen Ø, Wergeland S, Myhr KM, Sun SC, Berven FS.

J Proteomics Bioinform. 2016 Sep;9(9):209-219. Epub 2016 Sep 12.

27.

In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.

Kroksveen AC, Guldbrandsen A, Vaudel M, Lereim RR, Barsnes H, Myhr KM, Torkildsen Ø, Berven FS.

J Proteome Res. 2017 Jan 6;16(1):179-194. doi: 10.1021/acs.jproteome.6b00659. Epub 2016 Oct 26.

PMID:
27728768
28.

Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.

Bjørnevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2017 Jun;23(7):1018-1024. doi: 10.1177/1352458516671028. Epub 2016 Sep 23.

PMID:
27663872
29.

The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.

Grytten N, Skår AB, Aarseth JH, Assmus J, Farbu E, Lode K, Nyland HI, Smedal T, Myhr KM.

Mult Scler. 2017 Jun;23(7):1008-1017. doi: 10.1177/1352458516667240. Epub 2016 Sep 6.

PMID:
27600114
30.

Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Cortese M, Riise T, Bjørnevik K, Bhan A, Farbu E, Grytten N, Hogenesch I, Midgard R, Smith Simonsen C, Telstad W, Ascherio A, Myhr KM.

Ann Neurol. 2016 Oct;80(4):616-24. doi: 10.1002/ana.24769.

PMID:
27554176
31.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

32.

Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.

Bjørnevik K, Riise T, Benjaminsen E, Celius EG, Dahl OP, Kampman MT, Løken-Amsrud KI, Midgard R, Myhr KM, Torkildsen Ø, Vatne A, Grytten N.

Mult Scler. 2017 Feb;23(2):213-219. doi: 10.1177/1352458516646863. Epub 2016 Jul 11.

33.

Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood.

Keshari PK, Harbo HF, Myhr KM, Aarseth JH, Bos SD, Berge T.

BMC Genet. 2016 Apr 14;17:59. doi: 10.1186/s12863-016-0367-4.

34.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
35.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090
36.

Country break-out session highlights.

Fazekas F, Gehring K, Gallo P, Lebrun-Frénay C, Moral E, Myhr KM.

Neurodegener Dis Manag. 2015;5(6 Suppl):31-7. doi: 10.2217/nmt.15.58. Review.

PMID:
26611270
37.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

38.

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

PMID:
26531700
39.

Does low socioeconomic status in early life protect against multiple sclerosis? A multinational, case-control study.

Goulden R, Riise T, Myhr KM, Pugliatti M, Wolfson C.

Eur J Neurol. 2016 Jan;23(1):168-74. doi: 10.1111/ene.12830. Epub 2015 Oct 16.

PMID:
26475404
40.

Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015 Nov;132(5):368-9. doi: 10.1111/ane.12488. Epub 2015 Sep 15. No abstract available.

PMID:
26369381
41.

Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

Alme MN, Nystad AE, Bø L, Myhr KM, Vedeler CA, Wergeland S, Torkildsen Ø.

J Neuroimmunol. 2015 Aug 15;285:180-6. doi: 10.1016/j.jneuroim.2015.06.006. Epub 2015 Jun 19.

42.

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.

Kroksveen AC, Jaffe JD, Aasebø E, Barsnes H, Bjørlykke Y, Franciotta D, Keshishian H, Myhr KM, Opsahl JA, van Pesch V, Teunissen CE, Torkildsen Ø, Ulvik RJ, Vethe H, Carr SA, Berven FS.

Proteomics. 2015 Oct;15(19):3361-9. doi: 10.1002/pmic.201400142. Epub 2015 Sep 8.

PMID:
26152395
43.

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015;132(199):29-36. doi: 10.1111/ane.12428. Review.

44.

The Norwegian Multiple Sclerosis Registry and Biobank.

Myhr KM, Grytten N, Torkildsen Ø, Wergeland S, Bø L, Aarseth JH.

Acta Neurol Scand. 2015;132(199):24-8. doi: 10.1111/ane.12427. Review.

PMID:
26046555
45.

WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Holmøy T, Esbensen QY, Torkildsen Ø, Wergeland S, Bjerve KS, Beiske AG, Midgard R, Šaltytė-Benth J, Hovdal H, Myhr KM.

Acta Neurol Scand. 2016 Apr;133(4):309-12. doi: 10.1111/ane.12448. Epub 2015 Jun 2.

PMID:
26037530
46.

Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.

Bjørnevik K, Riise T, Cortese M, Holmøy T, Kampman MT, Magalhaes S, Myhr KM, Wolfson C, Pugliatti M.

Mult Scler. 2016 Jan;22(1):104-11. doi: 10.1177/1352458515579444. Epub 2015 May 26.

47.

The EnvIMS Study: Design and Methodology of an International Case-Control Study of Environmental Risk Factors in Multiple Sclerosis.

Magalhaes S, Pugliatti M, Casetta I, Drulovic J, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Lauer K, Myhr KM, Parpinel M, Pekmezovic T, Riise T, Wolfson D, Zhu B, Wolfson C.

Neuroepidemiology. 2015;44(3):173-81. doi: 10.1159/000381779. Epub 2015 May 7.

48.

Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.

Cortese M, Riise T, Bjørnevik K, Holmøy T, Kampman MT, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2015 Dec;21(14):1856-64. doi: 10.1177/1352458515578770. Epub 2015 May 6.

49.

Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study.

Ragnedda G, Leoni S, Parpinel M, Casetta I, Riise T, Myhr KM, Wolfson C, Pugliatti M.

J Neurol. 2015 May;262(5):1271-7. doi: 10.1007/s00415-015-7704-9. Epub 2015 Mar 21.

PMID:
25794863
50.

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Šaltytė Benth J, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2015 Mar 15;280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.

PMID:
25773151

Supplemental Content

Support Center